We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+12.62%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$615M
AUM Growth
+$85.2M
Cap. Flow
+$34.9M
Cap. Flow %
5.67%
Top 10 Hldgs %
53.32%
Holding
366
New
100
Increased
78
Reduced
73
Closed
88

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$19.3M
2
ASND icon
Ascendis Pharma A/S
ASND
+$14.9M
3
ZURA icon
Zura Bio
ZURA
+$14.1M
4
AAM
AA Mission Acquisition Corp
AAM
+$10.1M
5
ZLAB icon
Zai Lab
ZLAB
+$9.65M

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$25.2M
2
ROIV icon
Roivant Sciences
ROIV
+$12.8M
3
MRK icon
Merck
MRK
+$8.86M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$8.32M
5
QURE icon
uniQure
QURE
+$5.48M

Sector Composition

Rank Sector Weight
1 Healthcare 85.92%
2 Financials 3.35%
3 Communication Services 0.57%
4 Technology 0.47%
5 Utilities 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATXS
76
DELISTED
Astria Therapeutics
ATXS
$1.03M 0.17%
93,284
-44,874
-32% -$499K
LLY icon
77
Eli Lilly
LLY
$1.05T
$1.02M 0.17%
+1,150
New +$1.03M
SPRO icon
78
Spero Therapeutics
SPRO
$72.4M
$996K 0.16%
743,459
-175,470
-19% -$235K
ITCI
79
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$980K 0.16%
+13,400
New +$1.01M
AGIO icon
80
Agios Pharmaceuticals
AGIO
$1.89B
$946K 0.15%
+21,300
New +$967K
RVNC
81
DELISTED
Revance Therapeutics, Inc.
RVNC
$945K 0.15%
+182,166
New +$905K
MIRM icon
82
Mirum Pharmaceuticals
MIRM
$6.02B
$940K 0.15%
+24,100
New +$961K
REGN icon
83
Regeneron Pharmaceuticals
REGN
$80.1B
$916K 0.15%
+871
New +$969K
MCK icon
84
McKesson
MCK
$102B
$915K 0.15%
+1,850
New +$1.03M
CGEM icon
85
Cullinan Oncology
CGEM
$1.12B
$910K 0.15%
54,358
+1,097
+2% +$19.5K
SRPT icon
86
Sarepta Therapeutics
SRPT
$1.76B
$887K 0.14%
7,100
+2,650
+60% +$366K
TARS icon
87
Tarsus Pharmaceuticals
TARS
$2.84B
$852K 0.14%
+25,900
New +$728K
CLYM
88
Climb Bio
CLYM
$808M
$832K 0.14%
163,443
+65,748
+67% +$465K
ANSC
89
Agriculture & Natural Solutions Acquisition Corp
ANSC
$476M
$832K 0.14%
+80,362
New +$829K
AGR
90
DELISTED
Avangrid, Inc.
AGR
$823K 0.13%
23,000
– –
KVACU
91
DELISTED
Keen Vision Acquisition Corp Units
KVACU
$805K 0.13%
75,000
– –
CYTK icon
92
CALL
Cytokinetics
CYTK
$10.4B
$797K 0.13%
15,100
+15,000
+15,000% +$836K
PTCT icon
93
PTC Therapeutics
PTCT
$5.98B
$742K 0.12%
+20,000
New +$670K
DAWN
94
DELISTED
Day One Biopharmaceuticals
DAWN
$740K 0.12%
53,111
+18,011
+51% +$257K
CNTX icon
95
Context Therapeutics
CNTX
$47.3M
$733K 0.12%
373,835
-271,326
-42% -$602K
SLN
96
Silence Therapeutics
SLN
$564M
$732K 0.12%
40,290
– –
KPRX icon
97
Kiora Pharmaceuticals
KPRX
$11.5M
$719K 0.12%
196,551
+23,955
+14% +$93.5K
AMLX icon
98
Amylyx Pharmaceuticals
AMLX
$2.62B
$716K 0.12%
220,906
+113,600
+106% +$255K
PWSC
99
DELISTED
PowerSchool Holdings, Inc.
PWSC
$684K 0.11%
+30,000
New +$679K
AKRO
100
DELISTED
Akero Therapeutics
AKRO
$660K 0.11%
23,007
-2,500
-10% -$65.2K
2 3
4
5 6

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return

ADAR1 Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, ADAR1 Capital Management held 366 positions worth $615M, up 16% from $530M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

ADAR1 Capital Management deployed $34.9M of net new capital in Q3 2024, opening 100 new positions and adding to 78 existing holdings. Its largest new stake was Zura Bio: 3,770,649 shares worth $15.3M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 80% a quarter earlier, followed by Financials and Communication Services.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $25.2M trimmed.

  • ADAR1 Capital Management's largest Q3 2024 buy was Zura Bio: 3,770,649 shares worth $15.3M.
  • ADAR1 Capital Management added most to Immunovant in Q3 2024, an estimated $19.3M increase.
  • ADAR1 Capital Management's biggest Q3 2024 reduction was Protagonist Therapeutics, cutting an estimated $25.2M.
  • ADAR1 Capital Management fully exited uniQure in Q3 2024, selling an estimated $5.48M.
  • ADAR1 Capital Management's ten largest holdings make up 53% of its $615M portfolio in Q3 2024.
  • ADAR1 Capital Management opened 100 new positions and closed 88 in Q3 2024.
  • ADAR1 Capital Management's portfolio value rose 16% quarter-over-quarter to $615M.

Based on ADAR1 Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.